作者
Jürgen Wolf,Takashi Seto,Ji‐Youn Han,Noemı́ Reguart,Edward B. Garon,Harry J.M. Groen,Daniel S.W. Tan,Toyoaki Hida,Maja J.A. de Jonge,Sergey Orlov,Egbert F. Smit,Pierre-Jean Souquet,Johan Vansteenkiste,Maximilian J. Hochmair,Enriqueta Felip,Makoto Nishio,Michael Thomas,Kadoaki Ohashi,Ryo Toyozawa,Tobias R. Overbeck,Filippo de Marinis,Tae Min Kim,Eckart Laack,Anna Robeva,Sylvie Le Mouhaër,Maeve Waldron-Lynch,B. Sankaran,O. Alejandro Balbin,Xiaoming Cui,Monica Giovannini,Mikhail Akimov,Rebecca S. Heist
摘要
Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.
爱静静
寻道图强
乐乐乐乐乐乐
Frank
kento
yyymmma
樱桃猴子
fendy
Billy
jyy
zhouleiwang
浅尝离白
吃不饱星球球长
共享精神
领导范儿
shinysparrow
清脆松
tuanheqi
万能图书馆
sissiarno
皖公网安备34019202002308
